T3 Certain Tapered With DCD vs T3 Certain Tapered Non-DCD

This is a multicenter, prospective, randomized study that will assess the the safety and efficacy of the implant systems with:

• Resistance to countertorque testing (mobility)
• Implant Stability Quotient (ISQ)
• Changes in peri-implant crestal bone levels
• Confirmation of clinical benefits

A total of 60 implants, 30 per treatment group will be placed across all participating sites. One patient may contribute more than 1 implant. All implants/ patients will be followed for up to 2 years.

Inclusion criteria

• Patients of either sex and greater than 18 years of age
• Patients for whom a decision has already been made to use a dental implant in the mandible or maxilla.
• Immediate extraction or a prior extracted site
• Patients must be physically able to tolerate conventional surgical and restorative procedures.
• Presence of opposing dentition
• Patients who provide a signed informed consent.
• Patients who agree to be evaluated for each study visit.
• Minimum primary stability, insertion torque > 35Ncm

Exclusion criteria

• Patients with known systemic diseases such as uncontrolled diabetes, endocrine disease, heart disease, immuno-compromised, or mental disorders.
• Patients with current use of non-steroidal anti-inflammatory drugs, bisphosphonates or corticosteroid treatments.
• Patients with active infection or severe inflammation in the areas intended for implant placement.
• Patients with a > 10 cigarette per day smoking habit.
• Patients with a history of therapeutic radiation to the head or jaw.
• Patients who are known to be pregnant at the screening visit or planning to become pregnant within 6 months of study enrollment.
• Patients with evidence of severe parafunctional habits such as bruxing or clenching.
• Patients with HIV or Hepatitis infection